CagriSema and the October 2026 FDA Decision: What to Know
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
CagriSema is an investigational weight-loss medication that combines two ingredients in one weekly shot, and it is now under review by the FDA, with a decision widely expected sometime in 2026. It is not approved yet. This article explains what CagriSema is, what its large trials actually found, how those results sit next to today's approved medications, and what is known and not known about the timing of an FDA decision.
Who This Helps
This is for anyone following what is coming next in weight-loss medications and trying to separate solid information from hype. If you are comparing your current options or wondering whether to wait for something new, knowing where CagriSema really stands helps you plan without guesswork.
What CagriSema Is
CagriSema is a once-weekly injectable that pairs cagrilintide, which is a long-acting amylin analog, with semaglutide, which is a GLP-1 receptor agonist, in a single fixed dose. It is being developed by Novo Nordisk and is investigational, meaning it is not yet FDA-approved and is currently under FDA review (Novo Nordisk). The idea behind it is to combine two different appetite-related pathways in one medication rather than relying on a single mechanism.
What the Trials Found
In its main obesity trial, called REDEFINE 1, CagriSema led to substantial weight loss over 68 weeks. Among the more than 3,400 adults with obesity or overweight and no diabetes, those taking CagriSema lost about 22.7% of their body weight if they stayed on treatment, compared with about 2.3% on placebo, and the trial met its primary goals (Novo Nordisk). In the same trial, CagriSema produced more weight loss than either of its two ingredients used alone, with semaglutide alone at about 16.1% and cagrilintide alone at about 11.8%.
A second trial, REDEFINE 2, tested CagriSema in adults who had both obesity or overweight and type 2 diabetes. Over 68 weeks, participants lost about 15.7% of their body weight if they stayed on treatment, compared with about 3.1% on placebo (Novo Nordisk). Weight loss tends to be lower in people with type 2 diabetes across this class of medication, so that gap between the two trials is expected.
How It Compares to Wegovy and Zepbound
It helps to place CagriSema next to the two approved weekly injections people know best, while keeping in mind these results come from separate trials with different participants, so the numbers cannot be compared head to head. Zepbound, an FDA-approved medicine that contains tirzepatide, a dual GIP and GLP-1 receptor agonist, produced about 22.5% weight loss at its highest dose over 72 weeks in its own obesity trial (New England Journal of Medicine). Wegovy, an FDA-approved medicine that contains semaglutide, a GLP-1 receptor agonist, produced about 14.9% weight loss over 68 weeks in its main obesity trial (New England Journal of Medicine).
On side effects, CagriSema looked like the rest of this class, with stomach-related effects most common. In REDEFINE 1, gastrointestinal side effects were reported by about 80% of people on CagriSema, including nausea in about 55%, constipation in about 31%, and vomiting in about 26%, though only about 6% stopped the medication because of side effects (Novo Nordisk). Wegovy and Zepbound also commonly cause nausea, diarrhea, vomiting, and constipation in their own trials.
What this means for you: CagriSema's reported weight loss is in the same high range as today's strongest approved option, and it comes with the same kind of stomach-related side effects most people on these medications already know. It is not proven to be better than what is on the market, and it is not yet available, so it is one to watch rather than wait on indefinitely.
Where the FDA Decision Stands
Novo Nordisk submitted its application to the FDA for CagriSema for weight management on December 18, 2025, and the company has said the FDA is expected to review the application during 2026 (Novo Nordisk). No official FDA decision date has been publicly confirmed. The often-cited October 2026 timing is an unofficial estimate, based on the standard review period that typically follows a filing like this one, so treat it as a projected window rather than a set date. If the medication is approved, details like dosing, pricing, and how it compares in real-world use will become clearer at that point.
Final Takeaway
CagriSema is a promising weight-loss medication that is still under FDA review, not yet available to fill. Since it’s not yet FDA-approved, it should not be available from telehealth providers. Its large trials showed strong weight loss, in the same range as the most effective approved option, with the stomach-related side effects common to this class. It is not proven to be better than current medications, and the exact timing of an FDA decision has not been confirmed, with October 2026 being an estimate rather than an official date. If you are managing your weight now, there are approved options you and your clinician can use today. CagriSema is worth keeping an eye on, and there is no need to put your own plan on hold while you wait for it.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
AstraZeneca's elecoglipron, an experimental once-daily GLP-1 pill, is heading to Phase 3. See what the early results show and what is still unproven.
Retatrutide is not FDA approved, but some clinics sell it anyway. See what the science shows and why approval status matters for you.
The FDA approved Foundayo (orforglipron) on April 1, 2026. Here is what the new once-daily GLP-1 pill actually changes for patients.
Categories
Curated by
